Podcast: Treatment Intensification in mCSPC – The Nurse Perspective
Podcast: Treatment Intensification in mCSPC – The Nurse Perspective
Listen as GU oncology nurses share their views in this clinical update podcast
Listen as GU oncology nurses share their views in this clinical update podcast
Brenda Martone, Jennifer Sutton
In this podcast, oncology nurses Brenda Martone and Jennifer Sutton discuss how to use data to select the most appropriate treatments for patients with metastatic castration-sensitive prostate cancer. They also share the importance of being able to explain these clinical decisions to patients and reassure them that earlier intensive treatment can prolong overall survival without seriously impacting quality of life.
Brenda Martone
Oncology Nurse Practitioner
Northwestern Medicine
United States (US)
Brenda Martone is a board-certified adult nurse practitioner working in GU oncology at Northwestern Medicine, Chicago, IL. She graduated with her BSN from Concordia College/West Suburban College of Nursing in 1989, received her MSN/CNS degree from Loyola University in 1996 and then completed a post-master’s certificate to become an adult nurse practitioner from Rush University in 2008. Brenda is an advanced oncology certified nurse practitioner and has been an oncology nurse for over 31 years. She has been a member of several medical advisory boards, as well as developed programs about metastatic and non-metastatic castration-resistant prostate cancer. Brenda Martone is a frequent national and regional lecturer and a member of the Advanced Practitioner Society for Hematology and Oncology (APSHO).
Brenda Martone has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Bhealth and Pfizer.
Jennifer Sutton
Director of Nursing & Administration
Carolina Urologic Research Center
United States (US)
Jennifer Sutton is a registered nurse and the Director of Nursing and Administration at Carolina Urologic Research Center in Myrtle Beach, SC. After receiving her Bachelor of Science degree in Exercise Science with a minor in Chemistry from the University of South Carolina, she earned her Associate Degree in Nursing from Horry Georgetown Technical College. Jennifer is a member of the Society of Urologic Nurses and Associates, the Oncology Nursing Society, and the Association of Clinical Research Professionals (ACRP). She is an ACRP-certified Clinical Research Coordinator and has more than 11 years of experience managing and administering cutting edge therapies to patients with genitourinary malignancies and other urologic disorders. Additionally, she manages a team of research professionals that coordinate phase I-IV clinical trials in all areas of urology. In recent years, she has served on multiple prostate cancer and bladder cancer advisory boards and has published articles on emerging prostate cancer treatments and effective structuring and management of a clinical research center.
Jennifer Sutton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Bayer, Janssen, Merck, Myovant and SeSen Bio.
Podcast |
19 min
|
Jun 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical Takeaways
-
Treatment intensification with triplet therapy (ADT plus NHA plus docetaxel) should be the new standard of care for high-risk, high-volume, mCSPC patients who are fit for chemotherapy
-
Early treatment intensification should be considered for these patients whilst they are still well enough to tolerate intensive treatment
-
When determining which triplet regimen would be the most appropriate for your patient, it is important to consider the patient's co-morbidities, risk profile and potential drug-drug interactions
-
The nurse has a key role in communicating the benefits and risks of different triplet regimens to the patients
-
Patient education on potential side effects and early reporting of them is essential to optimise patient outcomes
This educational programme is supported by an Independent Medical Education Grant from Bayer
GU NURSES CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.